New insider activity at Doximity ( (DOCS) ) has taken place on February 14, 2025.
In recent transactions, Director Phoebe L. Yang Watkin sold 2,889 shares of Doximity stock, amounting to a total sale value of $217,195. Meanwhile, CEO Jeffrey Tangney made a more substantial move by selling 50,000 shares, which resulted in proceeds of $3,857,145.
Recent Updates on DOCS stock
Doximity’s stock has seen significant positive movement in the last 24 hours, with a notable rise of 35.1%. This surge follows the company’s impressive Q3 earnings report, which exceeded expectations and demonstrated strong revenue and EBITDA growth. Analysts have responded by raising their price targets for Doximity. Mizuho increased its target due to the company’s ‘beat and raise’ quarter, highlighting increased physician engagement and the introduction of a new pharma client portal. Goldman Sachs also raised its target, citing strong revenue trends and record high EBITDA margins as key drivers. Similarly, Truist adjusted its target upward, attributing the outperformance to successful new integrated programs and larger client commitments. Overall, Doximity’s robust financial performance, strategic product launches, and high client retention have been central to the optimistic revisions in price targets.
More about Doximity
YTD Price Performance: 40.37%
Average Trading Volume: 2,221,613
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $14.11B